Näytönastekatsaukset
Riitta Lassila ja Marko Vesanen
11.4.2023
Polven tekonivelleikkauksen jälkeen tukosprofylaksia tulisi jatkaa vähintään 10 vuorokautta.
Pitempää 30–42 vuorokauden tukosprofylaksia sovelletaan, jos potilaalla on
myös muita tukosvaaraa lisääviä tekijöitä. Lonkan tekonivelleikkauksen jälkeen tukosprofylaksia
jatketaan 30 vuorokautta.
Polven ja lonkan tekonivelleikkauksen tukosprofylaksia voidaan toteuttaa pienimolekulaarisella
hepariinilla (LMWH), fondaparinuuksilla tai suorilla antikoagulanteilla «Falck-Ytter Y, Francis CW, Johanson NA ym. Prevent...»1, «Bauer KA, Eriksson BI, Lassen MR ym. Fondaparinux ...»2, «Turpie AG, Bauer KA, Eriksson BI ym. Postoperative...»3, «Lassen MR, Raskob GE, Gallus A ym. Apixaban versus...»4, «Lassen MR, Gallus A, Raskob GE ym. Apixaban versus...»5, «Friedman RJ, Dahl OE, Rosencher N ym. Dabigatran v...»6, «Fuji T, Wang CJ, Fujita S ym. Safety and efficacy ...»7, «Fuji T, Fujita S, Kawai Y ym. Efficacy and safety ...»8, «Turpie AG, Lassen MR, Eriksson BI ym. Rivaroxaban ...»9.
- Tutkimuksen laatu: tasokas
- Sovellettavuus suomalaiseen väestöön: hyvä
Kirjallisuutta
- Falck-Ytter Y, Francis CW, Johanson NA ym. Prevention of VTE in orthopedic surgery
patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College
of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141:e278S-e325S
«PMID: 22315265»PubMed
- Bauer KA, Eriksson BI, Lassen MR ym. Fondaparinux compared with enoxaparin for the
prevention of venous thromboembolism after elective major knee surgery. N Engl J Med
2001;345:1305-10 «PMID: 11794149»PubMed
- Turpie AG, Bauer KA, Eriksson BI ym. Postoperative fondaparinux versus postoperative
enoxaparin for prevention of venous thromboembolism after elective hip-replacement
surgery: a randomised double-blind trial. Lancet 2002;359:1721-6 «PMID: 12049860»PubMed
- Lassen MR, Raskob GE, Gallus A ym. Apixaban versus enoxaparin for thromboprophylaxis
after knee replacement (ADVANCE-2): a randomised double-blind trial. Lancet 2010;375:807-15
«PMID: 20206776»PubMed
- Lassen MR, Gallus A, Raskob GE ym. Apixaban versus enoxaparin for thromboprophylaxis
after hip replacement. N Engl J Med 2010;363:2487-98 «PMID: 21175312»PubMed
- Friedman RJ, Dahl OE, Rosencher N ym. Dabigatran versus enoxaparin for prevention
of venous thromboembolism after hip or knee arthroplasty: a pooled analysis of three
trials. Thromb Res 2010;126:175-82 «PMID: 20434759»PubMed
- Fuji T, Wang CJ, Fujita S ym. Safety and efficacy of edoxaban, an oral factor Xa inhibitor,
versus enoxaparin for thromboprophylaxis after total knee arthroplasty: the STARS
E-3 trial. Thromb Res 2014;134:1198-204 «PMID: 25294589»PubMed
- Fuji T, Fujita S, Kawai Y ym. Efficacy and safety of edoxaban versus enoxaparin for
the prevention of venous thromboembolism following total hip arthroplasty: STARS J-V.
Thromb J 2015;13:27 «PMID: 26269694»PubMed
- Turpie AG, Lassen MR, Eriksson BI ym. Rivaroxaban for the prevention of venous thromboembolism
after hip or knee arthroplasty. Pooled analysis of four studies. Thromb Haemost 2011;105:444-53
«PMID: 21136019»PubMed